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Abstract 
It is becoming increasingly evident that deficits in the cortex and 
hippocampus at early stages of dementia in Alzheimer’s disease (AD) are 
associated to synaptic damage caused by oligomers of the toxic amyloid-β 
peptide (Aβ42). However, the underlying molecular and cellular mechanisms 
behind these deficits remain unknown. Here we provide evidence of a mechanism 
by which Aβ42 regulates neurotransmitter release.  We provide evidence that 
application of Aβ42 in cultured neurones is followed by its internalisation and 
translocation to synaptic contacts. Interestingly, our results demonstrate that 
Aβ42 is translocated at the presynaptic terminal of glutamatergic synapses where 
it interacts with Synaptophysin. This interaction disrupts the complex formed 
between Synaptophysin and Vamp2, increasing the amount of primed vesicles, 
exocytosis and baseline transmission. Our observations provide a necessary and 
timely insight into the cellular mechanisms that underlie the initial pathological 
events that lead to synaptic dysfunction in Alzheimer’s disease. 
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Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. The 
brain of AD patients is characterised by neuronal loss, the presence of 
extracellular senile plaques comprised of β-amyloid peptide (Aβ) and intracellular 
neurofibrillary  tangles (NFT) consisting of aggregates of hyperphosphorylated tau 
protein (Selkoe, 2001). Aβ, is derived from the proteolytic cleavage of the 
amyloid precursor protein (Thinakaran and Koo, 2008). The identification of Aβ as 
the major component of senile plaques led to the hypothesis that its extracellular 
deposition could be a key factor in the progression of AD (Hardy and Allsop, 
1991). Despite a clear association between Aβ build up and cognitive decline, a 
correlation between plaque deposition and the severity of dementia, could not be 
established. On the contrary, the cognitive decline is underlined by defects in 
synaptic plasticity (Gomez-Isla et al., 1997; Lambert et al., 1998; Selkoe, 2002; 
Cleary et al., 2005; Lesne et al., 2006) and by loss or dysfunction of synapses 
(Shrestha et al., 2006; Lacor et al., 2007; Shankar et al., 2007) that precede Aβ 
deposition and NFT formation (Hsia et al., 1999; Oddo et al., 2003; Oddo et al., 
2006). It is now believed that small soluble Aβ oligomers, are responsible for 
early synaptic changes (Selkoe, 2008).  
Although it is well established that Aβ affects long term potentiation (LTP) 
and long term depression (LTD), the causal mechanisms are still elusive(Hardy, 
2009). LTP in the hippocampus, is blocked upon application of Aβ in an NMDAR-
dependent manner (Cullen et al., 1997; Kim et al., 2001). Intriguingly though, at 
low concentrations Aβ induces LTP via an unknown mechanism (Puzzo et al., 
2008). Furthermore, Aβ induces LTD and excitotoxicity mediated by NMDARs 
receptors (Harkany et al., 2000). The importance of glutamate signalling via 
NMDARs as a causative event of dementia in AD is further demonstrated, by 
findings that memantine -a low affinity antagonist for NMDARs- results in 
behavioural improvement in AD model transgenic mice and is used as treatment 
of moderate AD (Scholtzova et al., 2008; Puangthong and Hsiung, 2009; Klyubin 
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et al., 2011). This raises the possibility that Aβ’s effects, could be due to an 
agonist action on NMDARs (Molnar et al., 2004). Since there is no conclusive 
evidence of a direct interaction between Aβ and NMDARs, proposals such as a 
reduction in glutamate uptake or an increase of glutamate release have been put 
forward to explain these findings (Arias et al., 1995; Harris et al., 1995; Kabogo 
et al., 2008; Puzzo et al., 2008; Abramov et al., 2009; Li et al., 2009; Li et al., 
2011), but the cellular mechanisms underlying these defects are not clearly 
understood. 
Here, we investigated the cellular and molecular mechanisms by which Aβ 
induces synaptic toxicity. We show that administration of Aβ42 peptides to 
mature hippocampal neurons is followed by its rapid internalisation. Subsequently, 
Aβ42 is detected at presynaptic terminals, where it can interact with 
Synaptophysin. We show that this interaction disrupts the Syp/Vamp2 complex, 
inducing an expansion of the primed synaptic vesicle pool and of baseline 
neurotransmission.  
Results 
Aβ interacts with Synaptophysin. 
To examine the underlining mechanisms behind Aβ42 induced 
excitotoxicity, we designed a proteomic screen, based on an affinity column of 
Aβ42, to identify synaptic proteins from hippocampal extracts that bind to the 
peptide. Bound proteins were first characterised by a candidate approach using 
antibodies against specific synaptic proteins to probe western blots. Among 
various proteins examined, Synaptophysin (Syp), a protein present at synaptic 
vesicles (SV) was detected at high levels (fig. 1a). Antibodies against additional 
pre-synaptic markers, such as synaptosomal-associated protein 25 (SNAP25) and 
vesicle associated protein 2 (Vamp2 or synaptopbrevin 2) failed to detect any 
protein in the eluted fractions. In addition, antibodies against postsynaptic 
proteins, such as the post synaptic density protein PSD95 were also used and 
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again no bands were observed (fig 1a). These results suggest that Syp is a strong 
candidate to be a specific interacting partner of Aβ42. 
Internalisation of Aβ42 in neurons 
We then explored the significance of this interaction in dissociated neurons. 
For this interaction to occur in vivo, Aβ42 should be present inside the neurons, 
at the presynaptic terminal. Aβ42 accumulates intracellularly via two possible 
avenues; either it builds up because part of the intracellular pool is not secreted, 
or extracellular Aβ42 is internalised by neurons(LaFerla et al., 2007). Thus, we 
developed an internalisation assay to investigate the dynamics and the 
subcellular distribution of externally administered synthetic Aβ42. Synthetic Aβ42 
is commercially available and readily aggregates in aqueous solution(El-Agnaf et 
al., 2000). Since soluble Aβ42 oligomers are believed to be the pathogenic 
peptides responsible for synaptic changes(Halene et al., 2009), we first ensured 
that oligomers were indeed present in our preparations, examining the 
aggregation state of Aβ42 by western blotting. Oligomeric Aβ42 species 
corresponding to trimers (molecular weight of approximately 12kDa), dimers 
(molecular weight of approximately 8kDa), as well as monomeric Aβ42 (molecular 
weight 4kDa) were consistently detected (fig 1b). We then established the 
optimum conditions that would allow detection of the peptide via immuno-
labelling and also ensure optimum survival of the neurons, applying different 
concentrations of Aβ42 to mature (21 DIV) dissociated hippocampal neurons.  
Our results showed that incubation of dissociated hippocampal neurons 
with a range of concentrations of Aβ42 (50-500nM) for 20 min, followed by 
recovery periods of 15min, 2hrs and 4hrs allowed both, detection of Aβ42 and 
optimum survival of neurons. To look into the dynamics of the internalisation of 
Aβ42, sequential immuno-labelling of fixed neurons was employed to distinguish 
between surface and internalised Aβ42. Surface labelling was carried out using 
the 6E10 primary antibody (for Aβ detection) and the Alexa-Fluor 488 secondary 
antibody in the absence of detergent.  The neurons were then post fixed and 
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intracellular Aβ42 was detected by repeating the procedure using the same 
primary antibody and the Alexa-Fluor 555 secondary antibody in the presence of 
0.1% Tween-20 to permeabilise the cells. After 15 min of recovery, a high degree 
of co-labelling was observed, suggesting the peptide remained extracellular (fig 
2a). However, with increased recovery time, although co-labelling was still 
evident, additional signal was increasingly observed after permeabilisation (fig 2b’, 
c’) showing that after 2hrs of recovery Aβ42 was internalised.  To quantify the 
extent of the internalisation,  co-localisation levels were quantified by calculating 
the split Mander’s co-localisation coefficients using the JACoP plugin for Image-
J(Bolte and Cordelieres, 2006). Mander’s co-efficient measures the coincidence of 
two signals, even when the intensities in both channels are significantly different. 
Our results (fig 2d) show that the Mander’s coefficient is highest (0.92±0.7 n=6) 
after the 15 min recovery time point, suggesting a high degree of co-localisation.  
Within a 2 hr recovery period, the Mander’s coefficient dropped significantly 
(0.64±0.07 n=10, student t-test p=0.0006). Similarly, after 4hrs of recovery, the 
Mander’s coefficient was lower than the 15 min recovery period (0.70±0.08 n = 8, 
student t-test p=0.0021) confirming that Aβ42 can be internalised over a 4h 
period (Saavedra et al., 2007).  
Presynaptic localisation of Aβ42.  
Since we identified Syp as a possible interacting partner of Aβ42, we 
investigated if such an interaction could mediate an internalisation/endocytosis of 
Aβ42 at synaptic contacts. Dissociated neurons were incubated with Aβ42 for 
20mins and allowed to recover in fresh media for 15mins or 2hrs prior to fixation. 
If Aβ42 was internalised via its interaction with Syp, we would expect Aβ42 to be 
localised at presynaptic terminals soon after incubation with the peptide. Double 
immuno-labelling for Aβ42 and Syp after 15 min of recovery, did not reveal any 
significant overlap between Aβ42 and synaptic contacts marked by Syp labelling 
(fig 3a, a’). Thus, it is unlikely that Aβ42 is internalised at synaptic contacts via 
its interaction with Syp. After 2hrs of recovery though, a significant increase of 
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co-localisation between Aβ42 and Syp labelling was observed (fig 3b, b’) 
suggesting that Aβ42 was localised at the presynaptic terminal. To further 
confirm our findings, we repeated the experiment using Vamp2 as an alternative 
presynaptic marker. Similar to our previous observations, after 15 min of 
recovery no overlapping pattern between Aβ42 and Vamp2 labelling was evident 
(fig 3c, c’), whereas after 2hrs of recovery, co-localisation between Vamp2 and 
Aβ42 was detected, further confirming its presence at pre-synaptic terminals. 
However, compared to Syp, co-localisation with Vamp2 was less evident (fig 3 d, 
d’). Furthermore, the pattern of Vamp2 staining after 2hrs of recovery, was 
unusual with visible stretches along the membrane (see brackets in fig 3d’’) 
instead of the characteristic punctate pattern (fig 3c).   
Aβ42 is specifically detected at glutamatergic synapses. 
The biochemical interaction of Aβ42 with Syp and its co-localisation with 
presynaptic markers implies that the peptide has a role in the pre-synaptic 
terminal. To further confirm our results and to investigate if the peptide was 
present at specific synapses, we performed double immuno-labelling for Aβ42 
with NMDARs in dissociated neurons incubated with Aβ42 for 20mins and allowed 
to recover in fresh media for 15mins or 2hrs prior to fixation.  
Double immuno-labelling for Aβ42 and NMDARs after 2hrs recovery 
revealed that Aβ42 was often juxtaposed to NMDARs (fig 4b), further confirming 
its presynaptic localisation.  In addition, after 15 min of recovery, labelling for 
Aβ42 and NMDARs was largely unrelated (fig 4a) suggesting that Aβ42 can be 
detected at synapses after prolonged recovery period. However, these result were 
unexpected since previous reports have demonstrated that incubation of 
dissociated neurons with Aβ peptides results entirely in its post-synaptic 
localisation(Lacor et al., 2004; Lacor et al., 2007; Pellistri et al., 2008). Since 
neurotransmitter release has been associated with rapid increase in the 
extracellular levels of Aβ42(Cirrito et al., 2005), we considered the possibility that 
the observed presynaptic localisation of Aβ42 could be transient, followed by its 
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release into the synaptic cleft in an activity dependent manner, where it 
subsequently can interact with postsynaptic targets. To test this hypothesis 
dissociated hippocampal neurons incubated with Aβ42 and allowed to recover for 
4h were depolarised with 50mM KCl to induce neurotransmitter release. Double 
immuno-labelling for Aβ42 and NMDARs showed that a substantial amount of 
Aβ42 was still juxtaposed to NMDARs (fig 4c), suggesting either that Aβ42 
remained presynaptic after neurotransmitter release or that it is released slowly 
at quantities below our detection threshold.    
Aβ42 disrupts the Syp/Vamp2 complex 
We next investigated the unusual distribution of Vamp2 in neurons 
exposed to Aβ42 (fig 3 d’’). It has been shown that Syp interacts with Vamp2 
regulating its synaptic distribution(Pennuto et al., 2003). Thus, we hypothesised 
that the diffuse distribution of Vamp2 could be a consequence of Aβ42 interfering 
with the formation of the Vamp2/Syp complex. To test this, we 
immunoprecipitated Vamp2 complexes from hippocampal extracts either in the 
presence of an excess of 100μM aggregated Aβ42, or in the presence of a similar 
concentration of control, scrambled Aβ40(Kowall et al., 1992) (fig 5a). A 
substantial reduction of co-immunoprecipitated Syp was observed in the presence 
of Aβ42, compared to the amount of co-immunoprecipitated Syp in the presence 
of the scrambled peptide (compare fig 5a lane 3 and 4) suggesting that Aβ42 
disrupts the interaction between Vamp2 and Syp in vitro.  
Since it has been shown that disruption of the interaction between Vamp2 
and Syp induces the axonal distribution of Vamp2(Pennuto et al., 2003), we 
compared the extent of co-localisation between these two proteins in neurons 
exposed to Aβ42 and control neurons to investigate if Aβ42 disrupts their 
interaction in living neurons as well. Double immuno-labelling of Vamp2 and Syp 
in control untreated neurons (fig 5b) and in neurons recovering for 15min after 
exposure to Aβ42 (fig 5c) showed the expected extensive co-localisation between 
the two proteins suggesting that Aβ42 had little or no effect on the Vamp2-Syp 
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complex during the first 15 min of recovery. On the contrary, Vamp2 labelling in 
neurons exposed to Aβ42 after 2h of recovery (fig 5d) showed stretches of 
Vamp2 immunoreactivity devoid of Syp labelling (i.e. areas between arrows in 
figure 5d). High magnification of boxed area in fig 5d demonstrates in detail 
Vamp2 labelling independent of Syp in what appears to be membrane fragments 
(brackets in fig 5d’’). This diffuse Vamp2 labelling is indicative of a disruption in 
the formation of the Vamp2/Syp complex in vivo (Pennuto et al., 2003) 
demonstrating that Aβ42 interferes with the stability of the interaction between 
Vamp2 and Syp. The co-localisation of Vamp2 and Syp was not affected in 
neurons exposed to similar concentration of the scrambled peptide (fig 5e) 
suggesting the diffuse Vamp2 labelling is specifically induced by Aβ42 and not by 
the addition of any peptide in the medium. Quantification of the extent of co-
localisation between Vamp and Syp, by calculating the Mander’s coefficient, 
confirmed that their co-localisation was specifically reduced in neurons exposed to 
Aβ42(fig 5f).  
Physiological consequences in synaptic transmission. 
Further to its role in sorting Vamp2, Syp also interacts with Vamp2 at the 
presynaptic terminal and it has been proposed that it regulates the participation 
of Vamp2 in the SNARE complex during the formation of the fusion pore complex 
(FPC)(Calakos and Scheller, 1994; Pennuto et al., 2002; Arthur and Stowell, 
2007). Therefore, disruption of the Vamp2-Syp complex at synaptic contacts by 
Aβ42 could induce the formation of the FPC resulting in an increase of primed SVs. 
To investigate this hypothesis, untreated mature hippocampal neurons, or 
neurons treated either with Aβ42 or with the scrambled peptide were incubated 
with FM1-43FX, a fluorescent lipophilic dye that labels membranes.  Using a 
hypertonic sucrose solution (500mM sucrose in HBSS) primed vesicles were 
induced to fuse to the presynaptic membrane and neurons were left to recover in 
the presence of the dye to allow for its uptake at sites of SV recycling(Gaffield 
and Betz, 2006). Incorporation of the dye at synaptic contacts was confirmed 
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with immuno-labelling for Syp. Images of mature (21DIV) untreated hippocampal 
neurons (fig 6a) and neurons treated either with Aβ42 (fig 6b) or scrambled 
peptide as a negative control (fig 6c) were taken consecutively leaving the 
microscope/camera settings unaltered.  
In untreated or control treated neurons, although internalisation of the dye 
was evident in the cell soma, the amount of internalised dye at synaptic contacts 
was not significant (n=20, fig 6a, b). On the contrary, neurons exposed to Aβ42 
consistently displayed a marked increase of the internalised dye at synaptic 
contacts (n=20), indicative of an increase in the number of vesicles primed to the 
presynaptic membrane (fig 6c). These results strongly support our hypothesis 
that Aβ42 increases the amount of primed vesicles at the presynaptic terminal. 
The question now was how this would affect synaptic transmission. To test this, 
we recorded excitatory post-synaptic responses (fEPSPs) from the CA1 region of 
hippocampal slices in response to electrical stimulation of the Schaffer collateral 
pathway, in the presence or absence of Aβ42. First, we noticed a concentration 
dependent enhancement in basic transmission at concentrations ranging from 
300pM to 1nM Aβ42 (fig 7a). We subsequently investigated in detail this effect by 
increasing electrical stimulation in slices exposed to 1nM Aβ42. Our results 
showed a progressive enhancement (p=0.044 at 50V) of recorded fEPSPs, in 
treated as compared with untreated, control slices (fig 7b) indicative of an 
increased efficacy of the Schaffer collateral synapse. We then confirmed the 
specificity of this enhanced efficacy either by chelation of Aβ42 using an excess of 
a specific antibody (6E10), or by using the scrambled peptide. Co-incubation with 
6E10 and Aβ42 produced similar recordings to untreated slices (fig 7c). 
Furthermore, incubation of slices with the scrambled peptide had no effect (fig 
7d) further confirming that the enhancement of fEPSPs was specific to Aβ42.  
To ensure that our results were not an artefact, we investigated in 
separate experiments if the same Aβ42 peptide used above could block LTP in 
hippocampal CA1 region. Our results showed that indeed it could reproduce the 
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established block of LTP (fig 7e, f) confirming that the effect we recorded was not 
an artefact.  To unambiguously confirm that the enhancement of synaptic 
transmission was induced by Aβ, we repeated our experiments with cell-derived 
Aβ peptides, from 7PA2 cells, [Chinese-hamster ovary (CHO) cells that express 
the V717F  mutant human APP] that produce and secrete significant amounts of 
low-n oligomers Aβ peptides(Podlisny et al., 1995). Our results with the cell 
derived peptides were similar to the ones obtained with the synthetic peptide 
suggesting that the effect we recorded was not an artefact of the synthetic 
peptide (Fig 8) but was rather a physiological function of the peptide.  
Discussion 
Synaptic localisation of Aβ42. 
Whilst extensive information in the literature shows that synaptic failure 
precedes cognitive decline in AD(Selkoe, 2002) the cellular and molecular events 
underlying this synaptic dysfunction remain obscure. The data presented here 
provide important insight into the mechanisms by which Aβ42 affects synaptic 
activity. First, we show that the presynaptic protein Synaptophysin interacts with 
Aβ42 in vitro. We then establish the significance of this interaction by showing 
that Syp and externally applied Aβ42 co-localise in living neurons. Studies with 
transgenic animal models for AD, have supported the presence of intraneuronal 
Aβ (iAβ) prior to the appearance of extracellular deposits, suggesting that iAβ is a 
significant contributor to the onset of learning and memory deficits(LaFerla et al., 
2007; Li et al., 2007). Despite an apparent relationship between the intracellular 
pool of Aβ and the extracellular deposits(Oddo et al., 2004; Oddo et al., 2006) 
the precise mechanism by which the peptide enters the neuron is still unknown. 
Physical interaction between Aβ42 and the α7 acetylcholine receptor(Nagele et al., 
2002) or apoE(Zerbinatti et al., 2006) has made these proteins candidates for a 
receptor mediated transfer of Aβ into the cell. On the other hand, there is 
evidence that Aβ peptides cross the neuronal membrane passively, via non-
endocytic and energy independent pathways, most likely due to its ability to 
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biophysically interact with lipids at the neuronal membrane(Kandimalla et al., 
2009). Thus, we considered if an interaction between Syp and Aβ42 at the 
presynaptic terminal could be an alternative mechanism to internalise the peptide. 
We examined the dynamics of the co-localisation of these proteins and found no 
supporting evidence since there was no indication of synaptic localisation of Aβ42 
in neurons that were left to recover for only 15min. Interestingly though, the 
absence of co-localisation at early time points compared to the co-localisation we 
observed after 2hrs of recovery, shows that Aβ42 requires time to accumulate at 
the presynaptic terminal. It is thus likely that Aβ42 is translocated to the 
presynaptic terminal by an unknown transport mechanism. Co-labelling for Aβ42 
and NMDARs further confirmed that Aβ42 is present  at presynaptic terminals, 
and similar to other reports, it is detected at glutamatergic synapses(Lacor et al., 
2007), suggesting the existence of an internalisation mechanism specific to 
glutamatergic neurons.  
Unlike the data presented here, several reports demonstrate exclusive co-
localisation between Aβ42 and postsynaptic markers(Lacor et al., 2004; Lacor et 
al., 2007). In such a study, Lacor and colleagues found 92% of exogenously 
applied Aβ co-localised with the post-synaptic protein PSD-95 and the majority of 
the peptide was found juxtaposed to Synaptophysin(Lacor et al., 2004).  We 
believe that the difference in our results reflects differences in our experimental 
procedures. For instance, a plausible explanation for our differences could be that 
we allowed cells to recover for two to four hours after exposure to Aβ42. This 
recovery period proved to be essential since localisation at presynaptic terminals 
could only be detected after prolonged recovery periods. In addition, Lacor et.al. 
showed that only high molecular weight species of Aβ peptides could be detected 
post-synaptically whereas our Aβ preparation was enriched in low oligomeric 
forms. Taken together, we believe that these results rather complement each 
other demonstrating different roles of Aβ. 
 Mechanism of synaptic toxicity 
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Confusing data regarding the effect of Aβ42 in synaptic dysfunction such 
as increase or suppression of spontaneous activity are often found in the 
literature (Hartley et al., 1999; Nimmrich et al., 2008). The underlying problem in 
resolving these inconsistencies has been to understand the mechanisms by which 
differences in the amount/preparation of the peptides can affect the outcome of 
an experiment. Furthermore, the ambiguousness of the causal mechanisms 
behind these effects has further challenged consistent interpretation of these data. 
We believe that our findings regarding the interaction between Aβ42 and Syp may 
help resolve some of these inconsistencies. Syp is a synaptic vesicle (SV) protein 
implicated in regulating the formation of the fusion pore complex (FPC) during SV 
fusion and exocytosis. It does so by forming hetero-dimeric complexes with 
Vamp2 (Synaptobrevin 2)(Calakos and Scheller, 1994), a SNARE protein(Sollner 
et al., 1993).  The complex between Vamp2 and Syp is formed at the trans-Golgi 
network (TGN), and the formation of this complex is necessary and sufficient to 
recruit Vamp2 to synaptic contacts. Disruption of this interaction, results in 
diffused localisation of Vamp2 along the axonal membrane(Pennuto et al., 2003). 
Here we demonstrate that Aβ42 disrupts the interaction between Vamp2 and Syp 
both in vitro and in dissociated neurons (fig 5).  Two possible mechanisms could 
account for this disruption: either Aβ42 disrupts a signalling pathway that 
regulates the dynamics of this interaction at the TGN, or it competes with Vamp2 
for binding to Syp.  Our IP data demonstrated that Aβ42 directly competes with 
Vamp2 for binding to Syp supporting the latter hypothesis. We also noticed that 
this disruption was more pronounced in less mature neurones (14 DIV) when 
synapses are not yet fully mature and there is increased traffic of structural 
components towards the developing synapses. Furthermore, we have no evidence 
supporting the presence of Aβ42 at the TGN at an early time point.   
In addition to correctly sorting Vamp2 at the synapse, Syp also prevents it 
from participating in the formation of the FPC(Edelmann et al., 1995; Pennuto et 
al., 2002). Thus, if Aβ42 competes with Vamp2 for binding to Syp at the synapse, 
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an increase in the number of primed vesicles at the presynaptic membrane would 
be expected due to an increased availability of Vamp2. We verified this by 
showing that inducing the fusion of primed SV in the presence of the lipophilic 
FM1-43FX dye results in an increase of endocytosed dye at the synapses of 
neurons incubated with Aβ42. Aβ42 induced changes to SV recycling has 
previously been reported. For instance, Kelly et.al. proposed that Aβ disrupts SV 
endocytosis, resulting in depleted SV pools(Kelly and Ferreira, 2007).  From a 
different perspective though, this depletion could be due to deregulation of 
SNARE complex formation ensuing from an increased availability of primed SVs. 
Indeed, the enhancement of single-shock fEPSPs by Aβ42 in living synapses 
within hippocampal slices suggested an increased availability of releasable 
synaptic vesicles. What is more, the same effect was reproduced by naturally 
produced amyloid peptides demonstrating that this effect is independent of the 
peptide source. It is important to note that we were also able to reproduce under 
our experimental conditions the well-established disruption of LTP by Aβ42.  
In support to our results, several reports have shown an Aβ-dependent 
increase in the number of vesicles available at the presynaptic active zone (Puzzo 
et al., 2008; Abramov et al., 2009; Parodi et al., 2010) or that glutamate release 
is enhanced by Aβ40 (Cuevas et al., 2011) , suggesting that regulation of NT 
release at the pre-synaptic level could be an important aspect of the physiological 
role of Aβ. Furthermore, increasing evidence suggest that Aβ could exert its 
effects in synaptic plasticity by excessive activation of NMDARs. For instance it 
has been shown that inhibition of LTP by Aβ can be through a mechanism 
involving both, excessive activation of extrasynaptic NMDARs or defects in 
glutamate uptake (Harris et al., 1995; Li et al., 2009; Li et al., 2011). Our results 
allow us to propose a model to describe the mechanism behind these 
observations (fig 9). We propose that low molecular weight Aβ oligomers at low 
concentrations increase the association of SV with the presynaptic membrane. It 
does so by disrupting the Vamp2-Syp complex through its interaction with Syp. 
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Consequently, Vamp2 becomes available to participate in the formation of SNARE 
complexes increasing the amount of primed SVs. Long term exposure and/or high 
levels of Aβ42 would consistently deregulate glutamate release, disrupting LTP 
(Kelly and Ferreira, 2007; Parodi et al., 2010; Li et al., 2011) and inducing 
excitotoxicity(Hynd et al., 2004). This model can also explain findings that show a 
“bell shaped” relationship between Aβ and synaptic plasticity(Abramov et al., 
2009). Finally, at later stages, increased release of Aβ42 from presynaptic sites 
would induce additional effects at the post-synaptic membrane (Cirrito et al., 
2005).  
An increasing number of reports in the past years demonstrate that 
glutamatergic synaptic transmission via AMPA, NMDA and metabotropic 
glutamate receptors is crucial in the pathogenesis of AD. Targeting these 
receptors for AD therapy although beneficial, comes with severe side effects. 
Thus, understanding the cellular mechanism behind the deregulation of 
glutamatergic neurotransmission might provide alternative therapeutic targets. 
Our data suggest a cellular mechanism that can account for the deregulation of 
glutamatergic synaptic transmission. Although it is quite possible that we have 
demonstrated only one of several cellular events disrupted by Aβ, understanding 
the causative events behind its toxicity is essential, in order to design appropriate 
therapeutic strategies to target the symptoms of AD more efficiently.  
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Materials and Methods 
Hippocampal cell culture: All animal experiments were performed according to 
home office regulations in appliance with the Animals Scientific Act 1986. Primary 
cultures of CA3-CA1 hippocampal neurons were prepared from E18 Wistar rat 
embryos. The experiments were performed in mature (21–28 days in vitro (DIV)) 
cultures. Neurons were seeded on poly-D-lysine (100µg/ml in 0.1M borate buffer) 
and laminin (5µg/ml in PBS) coated coverslips at a density of 75,000 cells per 
coverslip and  were maintained at 37°C, 5% CO2 in Neurobasal media, 
supplemented with B27, L-glutamine (0.5mM) and 100units/ml 
penicillin/streptomycin.  
Immunocytochemistry: Hippocampal cultures were rinsed once with PBS and 
fixed with 4% paraformaldehyde (PFA) in PBS. The coverslips were washed, 
permeabilised with 0.1% Tween-20 and 5% horse serum in PBS for 45 min at 
room temperature, followed by incubation with primary antibodies overnight at 
4°C. After washing, cells were incubated for two hours at room temperature with 
Alexa Fluor 488 or Alexa Fluor 555 (Molecular Probes). Primary antibodies used 
were: Anti-Aβ 6E10 (ID Labs (Ontario, Canada) and Abcam (Cambridge, UK)), 
Anti-NR2A/B (Millipore (Watford, UK)). All other primary antibodies were supplied 
by Abcam. For internalisation assays, fixed cells were incubated with 6E10 
followed by Alexa Fluor 488, then postfixed in 4% PFA for two minutes.  Cells 
were re-incubated with 6E10 in the presence of 0.1% Tween-20, followed by the 
secondary antibody Alexa Flour 555.  In all experiments, the cells were rinsed, 
mounted with ProLong reagent, and visualised on a spin disc confocal system 
(CARV from Digital Imaging Solutions) with an EM-CCD camera (Rolera/QI Cam 
3500) mounted in an Olympus X71 microscope with a 100x objective, using 
Image Pro 6.0 software. High magnification inlets were produced using Adobe 
photoshop. 
FM1-43FX Labelling: Following exposure to Aβ, a 5uM of FM1-43FX dye 
(prepared in HBSS warmed to 37°C) was applied to the cells for 5mins, followed 
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by application of a hypertonic 500mM sucrose solution in HBSS with 5uM FM1-
43FX.  After 5mins the sucrose solution was replaced with the original FM1-43FX 
solution for 15mins.  The cells were then washed twice for 15mins in HBSS to 
remove un-incorporated dye and were subsequently fixed in 4% 
paraformaldehyde.  Cells were kept in the dark until utilised.    
Protein extracts and Immunoprecipitation: Hippocampi were isolated from 
the brains of two juvenile Sprague Dawley rats (weighing between 90g and 140g) 
and homogenized in 1mL lysis buffer (25mM HEPES pH7.5, 150mM NaCl, 1% NP-
40, 10mM MgCl2, 1mM EDTA, 2% Glycerol), containing Sigma protease cocktail 
inhibitor. Protein G Dynabeads® (25uL) (Invitrogen) were incubated with 5μgr of 
the precipitating monoclonal antibody for one hour at 4°C. Scrambled peptide and 
Aβ42 were diluted in 100 μl hippocampal protein extracts (~7mg/ml) at a final 
concentration of 100μM and the mix was incubated with the antibody bound 
dynabeads at 4°C for 4 hours. Samples were boiled for 5mins to elute bound 
proteins, which were then analysed by SDS-PAGE.  
Immunoblot: Proteins were separated on NuPage 4–12% Bis-Tris gels at 200V 
and transferred to nitrocellulose membrane at 100Vfor one hour at 4°C in 
transfer buffer (200mM Glycine, 25mM Tris Base 20% Methanol). Blots were 
blocked with 5% nonfat dry milk in Tris-buffered saline (50mM Tris Base, 150mM 
NaCl) containing 0.1% Tween 20, pH 7.5, for one hour and incubated overnight 
at 4°C with primary antibody (1:250) and two hours with HRP-conjugated 
secondary antibody (1:1000). Membranes were developed with SuperSignal 
chemiluminescence kit according to instructions. 
Hippocampal Slice Preparation: Field potential recordings were made from 
ventral sections of postnatal day 32-42 Wistar rats.  Rats were deeply 
anesthetised by halothane prior to decapitation, and the brain rapidly removed 
and submerged in oxygenated (95% O2, 5%CO2) artificial cerebrospinal fluid 
(aCSF) containing 135mM NaCl, 3mM KCl, 1.25mM NaH2PO4, 1mM MgCl2, 10mM 
Glucose and 26mM NaHCO3.  The brain was hemisected, and ventral sections 
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(400µm thick) prepared in aCSF on a Vibroslice (Campden Instruments Ltd).  
Slices were transferred to a holding chamber of continually oxygenated aCSF and 
left to recover for at least one hour. 1nM final concentration of Aβ42, Aβ40 and 
scrambled Aβ peptide was added to the chamber to treat slices for 45 minutes 
prior to field EPSP recordings. One lyophilised fraction from 7PA2 cell media 
known to contain Aβ oligomers was re-suspended in 100ml aCSF in the tissue 
chamber to treat hippocampal slices for 45 minutes. 
Electrophysiology: Recordings of field excitatory post synaptic potentials 
(fEPSPs) were made from the stratum radiatum in the CA1 region of the 
hippocampus using low resistance glass electrodes, in response to stimulation of 
the Schaffer collateral commissural pathway using a monopolar borosilicate glass 
electrode driven by a constant voltage stimulator (Digitimer)  Dc. recordings were 
amplified using an AxoClamp2A (Molecular Devices) and a Neurolog NL104 
(Digitimer Ltd) and signals filtered at 3kHz prior to digitisation with a CED1401. 
Experiments were controlled using Signal 2 (CED Ltd) running on PC. Electrodes 
were positioned just below the tissue surface and slices were left to stabilise for 
20 minutes.  Input/output curves (or stimulation responses) were recorded, and 
the 10-90% slope measured, from a stimulus ranging from 10V to 70V with 3 
successive events at each input level, 30 seconds apart. To detect concentration 
dependent changes in neurotransmitter release, fEPSPs were initially evoked at 
50V with low frequency at 0.033 Hz in the presence of different concentrations of 
Aβ42. For LTP recordings, a stable baseline was maintained for 25 minutes at 
50% of the maximum fEPSP response, and LTP was induced by high frequency 
stimulation consisting of three trains of 100Hz, 10 seconds apart. Low frequency 
stimulation every 30 seconds for at least 90 minutes recorded the potentiated 
synaptic response. 
Synthetic Aβ peptides: Aβ42 (American Peptide USA) was prepared as 
described previously (El-Agnaf et al., 2000) and stored in 0.1M Tris pH7.4 at a 
stock concentration of 100μM at -20°C. Neurons were incubated with 50nM of 
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peptide for 20 minutes.  Following treatment, the media was replaced with fresh 
supplemented Neurobasal and the cells were left to recover for the specified 
times. 
Cell-Derived Aβ: 7PA2 cells are a CHO cell line stably expressing human APP751 
carrying the V717F AD causing mutation.  The Aβ peptides produced and secreted 
into the media of cultured 7PA2 cells were collected, concentrated and Aβ 
oligomers were separated by Size Exclusion Chromatography as previously 
described(Sian et al., 2000; Townsend et al., 2006)  
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Figure legends 
 Figure 1:  Identification of proteins interacting with Aβ by candidate 
approach. (a) Western blotting with primary antibodies against specific synaptic 
proteins. All antibodies, detected specific proteins in the starting material at their 
expected molecular weights (PSD95 at ~80kDa, Synaptophysin at ~38kDa, 
Vamp2 at ~19kDa and SNAP25 at ~25kDa).  Only the primary antibody against 
Synaptophysin detected a specific protein in the fraction eluted from the Aβ 
affinity column. (b) Oligomerisation state of Aβ42 compared to Aβ40 detected by 
western blotting. Monomeric Aβ peptides can be seen as a band at 4kDa. Only 
Aβ42 displayed visible low molecular weight aggregates. 
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Figure 2: Dynamics of Aβ42 internalisation by sequential immuno-labelling. 
Mature hippocampal neurons incubated with Aβ42 for 20 min were left to recover 
for a) 15 min, b) 2hrs and c) 4hrs.  Labelling for external (red) and internalised 
(green) Aβ42 showed extensive overlapping labelling after 15 min recovery 
period (a). a’ high magnification of boxed area in a. a’’ and a’’’ single channel 
views of a’. Arrows point towards examples of overlapping staining.  After 2hrs 
(b) or 4hrs (c) recovery period, less overlap was observed. b’ and c’ high 
magnifications of boxed areas in b and c respectively. b’’, c’’ and b’’’, c’’’ single 
channel views of b’ and c’. Arrowheads show examples of external and arrows of 
internalised Aβ42. d) Quantification of the extent of co-localisation shows a high 
degree of co-localisation at 15min recovery (M=0.92±0.07, n=6) compared to 
2hrs (M=0.64±0.07, student t-test p=0.0006, n=10) and 4hrs (M=0.70±0.08, 
student t-test p=0.0021, n=8) of recovery.  
Scale bar= 10μm. 
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Figure 3:  Presynaptic localisation of Αβ42. Mature hippocampal neurons, 
incubated with Aβ42 for 20 min were left to recover for 15 min (a and c), or 2hrs 
(b and d) prior to fixation. Co-labelling for Aβ42 and Syp (a) or Aβ42 and Vamp2 
(b) after 15 min recovery reveals distinct labelling patterns between Aβ42 and 
the presynaptic markers (n=15). a’ and c’ High magnifications of boxed areas in a 
and c respectively. a’’, c’’ and a’’’, c’’’ are single channel views of a’ and c’. Arrows 
in a’’ and c’’ point at Syp and Vamp2 positive synaptic contacts respectively 
whereas arrows in a’’’ and c’’’ show the relevant positions in the green channel. 
Co-labelling for Aβ42 and Syp (b) or Aβ42 and Vamp2 (d) after 2hrs recovery 
period shows co-localisation between Αβ and both presynaptic markers (n=39 for 
each condition).  b’ and d’ high magnification of boxed area in b and d 
respectively. b’’, d’’ and b’’’, d’’’ single channel views of b’ and d’.  Arrows in b’’ 
and b’’’ point at examples of Syp positive synaptic contacts that are also positive 
for Αβ42. Arrow at d’’ and d’’’ points at Vamp2 positive synaptic contacts that are 
also labelled for Αβ42. Bracket in d’’ shows diffuse Vamp2 staining evident only 
after the 2hrs recovery period.    
Scale bar= 10μm 
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Figure 4:  Presynaptic localisation of Αβ42 at glutamatergic synapses. 
Mature hippocampal neurons, incubated with Aβ42 for 20 min were left to recover 
for a) 15 min or b) 2hrs prior to fixation. a) Co-labelling for Aβ42 and NR2A/B  
after 15 min recovery period reveals distinct labelling patterns between them 
(n=20). a’ high magnification of boxed area in a. a’’ and a’’’ single channel views 
of a’.  Arrows in a’’ point at Αβ42 clusters and arrows in a’’’ show the relevant 
positions in the red channel.  b) Co-labelling for Aβ42 and NR2A/B after 2hrs 
recovery period shows juxtaposed labelling between them (n=18).  b’ high 
magnification of boxed area in b. b’’ and b’’’ single channel views of b’.  Arrows in 
b’’ point at Αβ42 clusters and arrows in b’’’ show the relevant positions in the red 
channel. c) Co-labelling for Aβ42 and NR2A/B after 4hrs recovery period followed 
by depolarisation by KCl still shows juxtaposed labelling between them (n=10). c’ 
high magnification of boxed area in c. c’’ and c’’’ single channel views of c’.  
Arrows in c’’ point at Αβ42 clusters and arrows in c’’’ show the relevant positions 
in the red channel.  
Scale bar= 10μm. 
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Figure 5: Disruption of the Syp/Vamp2 complex. a) Immunoprecipitation of 
Vamp2 from hippocampal homogenate assayed by western blotting for Vamp2 
and Syp. A band of 19kDa corresponding to Vamp2 and a band of 38kDa, 
corresponding to Syp were detected in all test conditions. A reduction in 
immunoprecipitated Syp is evident in the presence of aggregated Aβ42 (lane 3) 
when compared to control conditions (scrambled Aβ, lane 4) suggesting a 
disruption to the Vamp2-Syp complex.  Lane 6 shows absence of non-specific 
binding on the beads. b) Co-labelling for Syp and Vamp2 in untreated 
hippocampal neurons display a significant degree of co-localisation. c) Co-
labelling of Syp and Vamp2 in hippocampal neurons incubated with Aβ42 and 
allowed to recover for 15 min shows extensive co-localisation as well. d) After 
2hrs recovery period, Vamp2 staining is more diffuse with extensive stretches of 
Vamp2 immunoreactivity as indicated by arrows in c. c’ high magnification of 
boxed area in c. c’’ and c’’’ single channel images of c’. Bracket in c’’ shows 
diffuse Vamp2 labelling. e) Co-labelling for Syp and Vamp in hippocampal 
neurons, incubated with scrambled peptide and allowed to recover for 2h is 
similar to control. f) Quantification of co-localisation between Synaptophysin and 
Vamp2.  Aβ42 treated cells left to recover for two hour showed decreased level of 
co-localisation (0.85±0.09, n=24, student t-test p=0.0003) compared to control, 
untreated cells (0.961±0.03, n=24). Neurons left to recover for 15 min 
(0.99±0.02, n=24) or incubated with the scrambled peptide (0.99±0.01, n =18) 
did not display differences compared to control. 
Scale bar= 10μm.   
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Figure 6: Induction of primed SVs in hippocampal neurons to fuse to the 
presynaptic membrane labelled with Syp (green) is visualised by the 
internalisation of FM1-43FX dye (red). Internalised dye at synapses is near 
background levels in untreated (n=20) (a) as well as in neurons treated with the 
scrambled peptide (n=20) (b). a’ and b’ high magnifications of boxed areas in a 
and b respectively. a’’ and a’’’ single channel views of a’. b’’ and b’’’ single 
channel views of b’.  Arrows in a’’ and b’’ point at synaptic contacts labelled with 
Syp and arrows in a’’’ and b’’’ show the relevant positions in the red channel. c) 
Induction of docked SV fusion visualised by internalisation of FM1-43FX in 
neurons exposed to Aβ42 followed by 2hrs of recovery results in a significant 
increase in internalised dye (red) at synaptic contacts marked by Syp labelling 
(green) (n=20). c’ high magnification of boxed area in c). c’’ and c’’’ single 
channel views of c’. Arrows in c’’ point at synaptic contacts labelled with Syp and 
arrows in c’’’ point at the relevant positions in the red channel. 
Scale bar=10μm 
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Figure 7: (a)  fEPSPs recorded in the CA1 in response to a 50V stimulus of 
the Schaffer collateral commissural pathway showed that the effect of Aβ in 
fEPSPs is concentration dependent. Only mid-range concentrations of 0.3nM and 
1nM were able to increase the fEPSP slope (p=0.028 and p=0.048 respectively 
n=5 for each concentration tested). (b) Aβ42 increases the stimulation response 
compared to the response recorded in control, untreated slices over a range of 
stimuli. Results are presented as the percentage of the maximum fEPSP from 
control recordings (n≥5). Inlet in shows the trace of EPSP slopes between a 
control slice and a slice treated with Aβ42 stimulated at 50V.  (c) Chelation of 
Aβ42 using 6E10, a specific antibody for the peptide, abrogates the enhancement 
at all input values (n=5). (d) Scrambled Aβ did not induce increased responses 
compared to controls. (e) In control slices HFS potentiated the EPSP evoked for at 
least 120 minutes. The increase at 60 minutes after HFS was significant (students 
t-test p=0.0006 n=5). (f) Aβ42 treatment blocks the induction of long term 
potentiation (LTP) in hippocampal slices. After a 45 minute bath application of 
1nM Aβ42, HFS did not potentiate the EPSP slope.  
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Figure 8: ELISA assay from fractionated conditioned media from 7PA2 cells 
and control CHO cells detected Aβ oligomers in the conditioned medium of 7PA2 
cells but not of CHO control cells (a). Hippocampal slices were incubated with 
medium from fractions 12, 24 and 36 of the CHO control cells as well as the 7PA2 
cells. fEPSPs were recorded in response to Schaffer collateral commissural 
pathway stimulation at a range of stimulus from 10V through to 60V (b and d). 
Incubation with cell-derived Aβ, increased the response to stimulation at the CA1 
synapse (b) compared to slices treated with conditioned media from the control 
CHO cells (d). The results are expressed as a percentage of the maximum fEPSP 
slope from control slices.  Graphs showing representative results at 50V in slices 
exposed to 7PA conditioned medium (c) and to control CHO conditioned medium 
(e) show that cell derived Aβ increased fEPSP (student’s t-test p=0.003 n=5), 
whereas the control medium had no affect at 50V (n=5) (e). 
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Figure 9: A proposed model explaining the cellular and molecular mechanisms by 
which Aβ42 affects synaptic activity: Aβ42 is taken up by glutamatergic neurons 
and reaches the presynaptic terminal. At the presynaptic terminal, it disrupts the 
complex between Syp and Vamp2 (A), increasing the number of primed SVs (B). 
Consequently, Aβ42 increases the amount of neurotransmitter release, positively 
modulating synaptic plasticity at low concentrations (C). At high concentrations 
(or chronic exposure) aberrant neurotransmitter release rapidly depletes the SV 
pool disrupting LTP. In addition, aberrant glutamate release induces NMDARs 
signalling resulting in impairment of LTP, LTD induction, neuronal loss 
(excitotoxicity) and cognitive impairment seen in AD. Furthermore, in a 
concentration and time dependent manner, Aβ could be increasingly secreted 
from the presynaptic terminal directly affecting potential targets on the post-
synaptic membrane (C). Finally the SVs are endocytosed where they could either 
be reused or recycled (D). 
 
 
 
 
